Brief: Radiopharm Theranostics Receives FDA Orphan Drug Designation For Trivehexin (Rad 301) In Pancreatic Cancer
09/05/2023 13:12
May 9 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* RADIOPHARM THERANOSTICS RECEIVES FDA ORPHAN DRUG
DESIGNATION FOR
TRIVEHEXIN (RAD 301) IN PANCREATIC CANCER
Source text for Eikon: ID:nGNX7wXRgC
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM